Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

Microvascular Research

Volumn 69, Issue 1-2, 2005, Pages 56-63

  Dredge, Keith ^a,c   Horsfall, Rebecca ^a   Robinson, Simon P ^a   Zhang, Ling Hua ^b   Lu, Ling ^b   Tang, Yang ^b   Shirley, Michael A ^b   Muller, George ^b   Schafer, Peter ^b   Stirling, David ^b   Dalgleish, Angus G ^a   Bartlett, J Blake ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CELGENE CORPORATION   (United States)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Akt; Angiogenesis; CC 5013; IMiD ; Lenalidomide; Migration; Thalidomide

Indexed keywords

GROWTH FACTOR; LENALIDOMIDE; PROTEIN KINASE B;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; CELL MIGRATION; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM;

EID: 20144375457     PISSN: 00262862     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mvr.2005.01.002     Document Type: Article

References (23)

1. J.B. Bartlett, K. Dredge, and A.G. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat. Rev., Cancer 4 2004 314 322
2. J.B. Bartlett, A. Michael, and I.A. Clarke Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers Br. J. Cancer 90 2004 955 961
3. G. Bisping, R. Leo, and D. Wenning Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma Blood 101 7 2003 2775 2783
4. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
5. E. Chavakis, E. Dernbach, C. Hermann, U.F. Mondorf, A.M. Zeiher, and S. Dimmeler Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway Circulation 103 2001 2102 2107
6. J.D. D'Amato, M.S. Loughnan, E. Flynn, and J. Folkman Thalidomide is an inhibitor of angiogenesis Proc. Natl. Acad. Sci. 91 1994 4082 4085
7. S.R. Datta, A. Brunet, and M.E. Greenberg Cellular survival: a play in three Akts Genes Dev. 13 1999 2905 2927
8. K. Dredge, J.B. Marriott, and C.D. Macdonald Novel thalidomide analogs display anti-angiogenic activity independently of immunomodulatory effects Br. J. Cancer 87 2002 1166 1172
9. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 181 1971 182 186
10. Y. Fujio, and K. Walsh Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner J. Biol. Chem. 274 1999 16349 16354
11. B.M. Kenyon, F. Browne, and R.J. D'Amato Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization Exp. Eye Res. 64 1997 971 978
12. M. Morales-Ruiz, D. Fulton, and G. Sowa Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt Circ. Res. 86 2000 892 896
13. G.W. Muller, L.G. Corral, and M.G. Shire Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity J. Med. Chem. 39 1996 3238 3240
14. G.W. Muller, R. Chen, and S.Y. Huang Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production Bioorg. Med. Chem. Lett. 9 1999 1625 1630
15. K. Norrby Basic fibroblast growth factor and de novo mammalian angiogenesis Microvasc. Res. 48 1994 96 113
16. K. Norrby Vascular endothelial growth factor and de novo mammalian angiogenesis Microvasc. Res. 51 1996 154 163
17. K. Norrby, and P. Ostergaard Basic-fibroblast-growth-factor-mediated de novo angiogenesis is effectively suppressed by low-molecular-weight than by high-molecular-weight heparin Int. J. Microcirc. 16 1996 8 15
18. T. O'Brien, D. Cranston, S. Fuggle, R. Bicknell, and A.L. Harris Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer Cancer Res. 57 1 1997 136 140
19. P.G. Richardson, R.L. Schlossman, and E. Weller Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 2002 3063 3067
20. I. Shiojima, and K. Walsh Role of Akt signalling in vascular homeostasis and angiogenesis Circ. Res. 90 2002 1243 1250
21. S. Singhal, J. Mehta, and R. Desikan Antitumour activity of thalidomide in refractory multiple myeloma N. Engl. J. Med. 341 1999 1565 1571
22. P. Workman, P. Twentyman, and F. Balkwill United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia, second edition Br. J. Cancer 77 1998 1 12
23. L. Yang, H.C. Dan, and M. Sun Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt Cancer Res. 64 2004 4394 4399